Type 1 diabetes has traditionally been considered a T-cell-mediated autoimmune disease. However, recent studies have shown that treatment of newly diagnosed type 1 diabetes patients with rituximab (ant-CD20 antibody) had a significant effect in slowing down the progression of their disease. These results indicate that autoantibodies likely contribute to the process of pancreatic $\beta$-islet cell destruction in these patients.

Question

Quizplus · Accepted Answer

Recent studies have shown that autoantibodies likely contribute to the process of pancreatic islet cell destruction in patients with type 1 diabetes. Treatment with rituximab, an anti-CD20 antibody, has been found to slow down the progression of the disease in newly diagnosed patients, indicating that B-cells and autoantibodies play a role in the pathogenesis of type 1 diabetes.

Type 1 Diabetes Has Traditionally Been Considered a T-Cell-Mediated Autoimmune β\betaβ

Type 1 Diabetes Has Traditionally Been Considered a T-Cell-Mediated Autoimmune $\beta$